AVEO and Schering-Plough to Develop Anti-HGF Antibody
AVEO and Schering-Plough to Develop Anti-HGF Antibody
CAMBRIDGE, MassachusettsAVEO Pharmaceuticals, Inc. has entered into an exclusive worldwide agreement with Schering-Plough Corporation to develop and commercialize AV-299, a highly potent antagonist of hepatocyte growth factor/scatter factor (HGF/SF). The antibody has shown excellent efficacy in preclinical models of human cancer and is expected to enter clinical trials in early 2008, the companies announced in a press release.
Articles in this issue
Escalating Drug Costs Could Provoke Consumer Backlash
Androgen Deprivation Therapy Linked to Increased Cardiac Disease Mortality Risk
Large Study Casts Doubt on Value of CAD
Cetuximab Does Not Increase Mucositis in H&N Cancer
2004 Update Shows Continued Lower Breast Ca Incidence
Reclast Single-Dose Infusion Approved for Paget's Disease
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
